Who are Theravance Biopharma, Inc.'s main suppliers?

Theravance Biopharma, Inc. (TBPH) key suppliers include: Merck & Co., Inc., ORANY, ORANY, Regeneron Pharmaceuticals, Inc., Royalty Pharma plc and 3 more. View the full supplier network at chainsifter.com/chain/TBPH.

Who are Theravance Biopharma, Inc.'s major customers?

Theravance Biopharma, Inc. (TBPH) key customers include: VIATRIS, ACCORD-HEALTHCARE-INC, CIPLA-LIMITED, CIPLA-USA-INC, EUGIA-PHARMA-SPECIALTIES-LTD and 17 more. View the full customer network at chainsifter.com/chain/TBPH.

What sector is Theravance Biopharma, Inc. in?

Theravance Biopharma, Inc. (TBPH) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Theravance Biopharma, Inc. Suppliers, Customers & Supply Chain (TBPH)

8Suppliers

22Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Theravance Biopharma, Inc. (TBPH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

33Total relationships

4Distinct source URLs

13High confidence

0.785Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Theravance Biopharma, Inc. Suppliers

Ticker	Name	Confidence	Evidence
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from MRK grap…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	graphic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or divest an asset that we designate as outside our core business, where we believe the …
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN g…
RPRX	Royalty Pharma plc	72%	Reciprocal relationship from RPRX graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX g…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from TBPH graph: graphic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or di…
SNYNF	Sanofi	72%	graphic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or divest an asset that we designate as outside our core business, where we believe the …
VTYX	Ventyx Biosciences Inc	72%	Reciprocal relationship from VTYX graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc…

Theravance Biopharma, Inc. Customers

Ticker	Name	Confidence	Evidence
VIATRIS	VIATRIS	92%	Under the terms of the Viatris Agreement, which included the delivery by the Company of a license to Viatris to develop and commercialize revefenacin, Viatris was responsible for reimbursement of the…
ACCORD-HEALTHCARE-INC	ACCORD-HEALTHCARE-INC	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
CIPLA-LIMITED	CIPLA-LIMITED	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
CIPLA-USA-INC	CIPLA-USA-INC	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
EUGIA-PHARMA-SPECIALTIES-LTD	EUGIA-PHARMA-SPECIALTIES-LTD	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
LUPIN-PHARMACEUTICALS-INC	LUPIN-PHARMACEUTICALS-INC	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
ORBICULAR-PHARMACEUTICAL-TECHNOLOGIES-PRIVATE-LI	ORBICULAR-PHARMACEUTICAL-TECHNOLOGIES-PRIVATE-LI	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
QILU-PHARMACEUTICALS-CO-LTD	QILU-PHARMACEUTICALS-CO-LTD	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
TEVA-PHARMACEUTICALS-INC	TEVA-PHARMACEUTICALS-INC	90%	As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular …
MANKIND-PHARMA-LTD	MANKIND-PHARMA-LTD	80%	The patent litigation against the one remaining generic company, Mankind Pharma Ltd., along with certain affiliates, remains pending.
GSK	GSK plc	72%	ditional clarity regarding any remaining value in ampreloxetine for our shareholders. There can be no assurance that any additional regulatory engagement will occur. Organizational Restructure Whil…
GSK	GSK plc	72%	Reciprocal relationship from GSK graph: Reciprocal relationship from TBPH graph: ditional clarity regarding any remaining value in ampreloxetine for our shareholders. There can be no assurance that a…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from TBPH graph: payers may limit coverage to specific…
MRK	Merck & Co., Inc.	72%	payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payers are increa…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their sa…
ORANY	ORANY	72%	and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in ord…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN g…
REGN	Regeneron Pharmaceuticals, Inc.	72%	payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payers are increa…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from SNYN…
SNYNF	Sanofi	72%	and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in ord…
VTYX	Ventyx Biosciences Inc	72%	Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandio…
THERAVANCE-RESPIRATORY-COMPANY-LLC	THERAVANCE-RESPIRATORY-COMPANY-LLC	62%	solidated statements of operations. The Company’s sublease income from its subleases is summarized below: Three Months Ended March 31, (In thousands) 2026 2025 Suble…

Theravance Biopharma, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TBPH-DEBT	Debt stack $40.5M	90%	Market cache reports total debt of $40.5M.
TBPH-DEBT-12897	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2022-06-30.

Theravance Biopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Theravance Biopharma, Inc..

Theravance Biopharma, Inc. Ownership

Holder	Name	Confidence	Evidence
TBPH-OWNER-MADISON-AVENUE-PARTNERS-LP	Madison Avenue Partners, LP	90%	13F overlay lists Madison Avenue Partners, LP as top holder; 174 tracked holders.

Theravance Biopharma, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
AZN	AstraZeneca PLC	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2

Theravance Biopharma, Inc. Supply Chain